Systemic pyoderma gangrenosum responding to infliximab and adalimumab

Hubbard, V. G.; Friedmann, Adam; Goldsmith, Portia

doi:10.1111/j.1365-2133.2005.06467.x

Cited by 101 publications

(76 citation statements)

References 15 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Etanercept has also been successfully used in some cases of PG without underlying IBD [79,80,81]. In addition, another patient, allergic to infliximab, responded to adalimumab after prior failure of etanercept [82]. More generally, anti-TNF agents are now widely used for other dermatological diseases.…”

Section: Discussionmentioning

confidence: 99%

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

Juillerat¹,

Christen-Zäch

Troillet³

et al. 2007

Dermatology

View full text Add to dashboard Cite

We report the case of a 19-year-old woman who developed an acute disseminated pyoderma gangrenosum (PG) during a severe flare of ulcerative colitis (UC). She was successfully treated with a 3-dose regimen of the anti-tumor-necrosis-factor-α antibody infliximab. The literature on the effectiveness of this biological agent was reviewed, including 8 other cases of UC-associated PG and 77 cases of Crohn’s-disease-associated PG. This case report and the review of the literature demonstrate that infliximab can be successfully used to treat patients with PG associated with inflammatory bowel diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

Juillerat¹,

Christen-Zäch

Troillet³

et al. 2007

Dermatology

View full text Add to dashboard Cite

show abstract

“…Diğer tedavi seçenekleri arasında plazmaferez, IVIG, talidomid, kolşisin, siklofosfamid, metotreksat, sülfasalazin yer almaktadır 58,61,69,85,86 . Son zamanlarda özellikle inflamatuvar barsak hastalığı ile ilişkili dirençli PG olgularında TNF-α blokerlerinin (infliksimab, etanersept, adalimumab) oldukça başarılı olduğu bildirilmiştir 62,65,[91][92][93][94][95] . Tedavideki son gelişmelere rağmen, PG'li hastaların uzun dönemde sonuçları öngörülememekte, bazı serilerde mortalite oranı %30 olarak bildirilmektedir.…”

Section: Subkorneal Püstüler Dermatozunclassified

Paraneoplastik özellik gösteren reaktif dermatozlar

Ekinci¹,

Aslan²

2013

TURKDERM

View full text Add to dashboard Cite

ÖzetReaktif dermatozlar infeksiyonlar, inflamatuar hastalıklar, ilaç kullanımı ve maligniteler başta olmak üzere birçok nedenle ortaya çıkabilirler. Böyle bir dermatozla karşılaşan hekimler dermatozu tedavi etmenin yanı sıra altta yatan nedeni araştırmaya da yönelirler. Bu derlemede, reaktif dermatozların paraneoplastik potansiyelleri değerlendirilerek tanı sonrası etyoloji, takip ve tedavide yapılması gerekenler irdelenmiştir. Sum maryReactive dermatoses may occur related to many underlying causes including infections, inflammatory diseases, medications and malignancies. In the management of these dermatoses the investigation of underlying cause is crucial besides the therapy of dermatosis. In this review, mainly the paraneoplastic potentials of reactive dermatoses have been evaluated and additionally the etiology, follow-up and treatment have been discussed. Recent literature about figurated erythemas (erythema annulare centrifugum, erythema gyratum repens, necrolytic migratory erythema), neutrophilic dermatoses (Sweet's syndrome, pyoderma gangrenosum, subcorneal pustular dermatosis) and erythema nodosum have been scrutinized. (Turkderm 2013; 47: Suppl 2: 69-77) Key Words: Paraneoplasia, reactive dermatoses, Sweet syndrome, erythema gyratum repens, necrolytic migratory erythema, erythema annulare centrifugum, subcorneal pustular dermatosis, erythema nodosum, pyoderma gangrenosum

show abstract

“…The treatment of IBD with extraintestinal manifestation has advanced in parallel to our increasing understanding of its pathomechanism [5][6][7][8][9] . One of the most well recognized proinflammatory mediators involved in the pathogenesis of IBD is tumor necrosis factor α (TNF-α).…”

Section: Discussionmentioning

confidence: 99%

Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone

Zöld¹,

Nagy²,

Dévényi³

et al. 2009

WJG

View full text Add to dashboard Cite

Crohn's disease (CD) is a chronic relapsing and remitting autoinflammatory disorder of the gastrointestinal tract that has many intestinal and extraintestinal complications. The purpose of treatment is long-term remission, reduction of complications, and improvement of patients' quality of life. In many cases, this can be quite challenging and it is necessary to have a well thought out management strategy. We present the case of a 38-year-old woman with fistulizing CD that manifested as diffuse abdominal pain and bloody diarrhea accompanied by arthralgia. In addition, there were ulcerative lesions surrounded by cutaneous inflammation and erythema on her extremities, indicative of pyoderma gangrenosum. The patient was treated with high doses of parenteral methylprednisolone without any improvement and was started on adalimumab. A positive response to adalimumab therapy was observed: after 2 mo of therapy, the ulcerative skin lesion healed completely and the enterogastric fistula was closed after 5 mo adalimumab treatment. Adalimumab might be a suitable initial as well as maintenance therapy in patients with complicated CD.

show abstract

Systemic pyoderma gangrenosum responding to infliximab and adalimumab

Cited by 101 publications

References 15 publications

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

Paraneoplastik özellik gösteren reaktif dermatozlar

Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone

Contact Info

Product

Resources

About